Loading...
Up to 40% of HIV-infected patients who receive the recommended standard-dose, inactivated, trivalent seasonal influenza vaccine do not respond to it. Researchers have now randomized 195 HIV-infected patients (70% men; 70% black; 89% on antiretroviral therapy) to receive high-dose (60-µg) influenza vaccine or the standard 15-µg vaccine. A serum hemagglutinin inhibition assay was used to measure antibody response.
Seroprotection rates were significantly higher with the high-dose than with the standard-dose vaccine for the H1N1 (96% vs. 87%) and influenza B strains (91% vs. 80%) — and nonsignificantly higher for the H3N2 strain (96% vs. 92%). Seroconversion rates followed that same pattern, and postvaccination geometric mean antibody titers for…